Genethon, a pioneer and leader in gene therapy for rare diseases, unveiled results at the MDA Conference in Orlando confirming the long-term efficacy of its GNT0004 gene therapy in Duchenne muscular ...

Genethon and Eukarÿs announce a strategic partnership to develop a breakthrough technology to reduce the biomanufacturing cost of gene therapies Evry, January 23, 2025- Genethon, a pioneer and leader ...

LUND, Sweden & EVRY, France--(BUSINESS WIRE)--Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA) and Genethon, a pioneer and a leader in gene therapy research and development for rare genetic diseases, ...

The MarketWatch News Department was not involved in the creation of this content. -- The Duchenne muscular dystrophy (DMD) patients experiencing long-term efficacy were treated with the therapeutic ...

PARIS, January 26, 2026--(BUSINESS WIRE)--Genethon, a unique non-profit gene therapy R&D organization founded by the French Muscular Dystrophy Association (AFM-Telethon), began the new year with an ...

Evry (France) - January 9th, 2020 - Genethon, a French laboratory dedicated to the design and development of gene therapy products for rare diseases, and Sarepta Therapeutics, the leader in precision ...

Tuesday, April 28, during a ceremony at the Elysee Palace, Genethon, the laboratory of the AFM-Telethon, was named recipient of the Global Innovation Competition 2030 in the category 'Risk lift' The ...

Sarepta Therapeutics has announced a new collaboration with Genethon for gene therapy research in efforts to develop new Duchenne muscular dystrophy (DMD) treatments. Sarepta Therapeutics has ...

Généthon, which carries out gene therapy R&D for rare genetic diseases, and Thales, a European artificial intelligence specialist, are working together to develop digital models for improving gene ...

Genethon, dedicated to designing and developing gene therapy products for rare diseases, received this Monday 30th of November the authorization from the ANSM, the French National Agency for Medicines ...

The trial will be conducted in patients with pre-existing anti-AAV antibodies which limit use of gene therapy treatment LUND, Sweden & EVRY, France, December 03, 2024--(BUSINESS WIRE)--Hansa Biopharma ...